In vitro activities of various antibiotics, alone and in combination with colistin methanesulfonate, against Pseudomonas aeruginosa strains isolated from cystic fibrosis patients

Chemotherapy

Volumn 54, Issue 2, 2008, Pages 147-151

  Güzel, Çaǧla Bozkurt ^a   Gerçeker, A Alev ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Antibiotic combinations; Colistin methanesulfonate; Cystic fibrosis; Pseudomonas aeruginosa

Indexed keywords

AMIKACIN; BETA LACTAM ANTIBIOTIC; CEFTAZIDIME; COLISTIMETHATE; COLISTIN; MEROPENEM;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CYSTIC FIBROSIS; DRUG POTENTIATION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

ANTI-BACTERIAL AGENTS; COLISTIN; CYSTIC FIBROSIS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; HUMANS; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 41349119670     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000119741     Document Type: Article

References (23)

1. Miller MB, Gilligan PH: Laboratory aspects of management of chronic pulmonary infections in patients with cystic fibrosis. J Clin Microbiol 2003;41:4009-4015.
2. Koyama Y, Kurosasa A, Tsuchiya A, Takakuta K: A new antibiotic 'colistin' produced by spore-forming soil bacteria. J Antibiot 1950;3:457-458.
3. Schwartz BS, Warren MR, Barkley FA, Landis L: Microbiological and pharmacological studies of colistin sulphate and sodium colistin methanesulfonate. Antibiot Annu 1960;7:41-60.
4. Hancock REW, Chapple DS: Peptide antibiotics. Antimicrob Agents Chemother 1999;43:1317-1323.
5. Clinical and Laboratory Standards Institute (CLSI) 2006: Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically (ed 7). Approved Standard M7-A7. Wayne, CLSI, 2006.
6. Wu M, Hancock REW: Interaction of the cyclic antimicrobial cationic peptide bactenecin with the outer and cytoplasmic membrane. J Biol Chem 1999;274:29-35.
7. National Committee for Clinical Laboratory Standards (NCCLS) 1999: Methods for Determining Bactericidal Activity of Antimicrobial Agents: Approved Guideline M26-A. Wayne, NCCLS, 1999.
8. Pillai SK, Moellering RC Jr, Eliopoulos GM: Antimicrobial combinations; in Lorian V (ed): Antibiotics in Laboratory Medicine 5. Philadelphia, Lippincott Williams and Wilkins, 2005, pp 365-440.
9. Lyczak JB, Cannon CL, Pier GB: Lung infections associated with cystic fibrosis. Clin Microbiol Rev 2002; 15: 194-222.
10. Frederiksen B, Koch C, Hoiby N: Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol 1997; 23: 330-335.
11. Taccetti G, Campana S, Festini F, Mascherini M, Döring G: Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients. Eur Respir J 2005; 26: 458-461.
12. Catchpole CR, Andrews JM, Brenwald N, Wise R: A reassessment of the in vitro activity of colistin sulphomethate sodium. J Antimicrob Chemother 1997; 39: 255-260.
13. Hogardt M, Schmoldt S, Götzfried M, Adler K, Heesemann J: Pitfalls of polymyxin antimicrobial susceptibility testing of Pseudomonas aeruginosa isolated from cystic fibrosis patients. J Antimicrob Chemother 2004;54:1057-1061.
14. Byrne S, Maddison J, Connor P, Doughty I, Dodd M, Jenney M, Webb AK, David TJ: Clinical evaluation of meropenem versus ceftazidime for the treatment of Pseudomonas spp. infections in cystic fibrosis patients. J Antimicrob Chemother 1995;36(suppl A):135-143.
15. Sumita Y, Fukasawa M, Okuda T: Comparison of two carbapenems, SM-7338 and imipenem: affinities for penicillin-binding proteins and morphological changes. J Antibiot (Tokyo) 1990;43:314-320.
16. Köhler T, Hamzehpour MM: Carbapenem activities against Pseudomonas aeruginosa: respective contributions of OprD and efflux systems. Antimicrob Agents Chemother 1999;4:424-427.
17. Aktas Z, Poirel L, Salcioglu M, Ozcan PE, Midilli K, Bal C, Ang O, Nordmann P: PER-1 and OXA-10-like β-lactamases in ceftazidime-resistant Pseudomonas aeruginosa isolates from intensive care unit patients in Istanbul, Turkey. Clin Microbiol Infect 2005;11:193-198.
18. Danel F, Hall LMC, Duke B, Gur D, Livermore DM: OXA-17, a further extended-spectrum variant of OXA-10 β-lactamase, isolated from Pseudomonas aeruginosa. Antimicrob Agents Chemother 1999;43:1362-1366.
19. Doring G, Conway SP, Heijerman HG, Hodson ME, Hoiby N, Smyth A, Touw DJ: Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J 2000;16:749-767.
20. Bodmann KF: Current guidelines for the treatment of severe pneumonia and sepsis. Chemotherapy 2005;51:227-233.
21. Katou K, Nakamura A, Kato T, Tonegawa K, Kutsuna T, Niwa T, Morita H, Itoh M: Combined effects of panipenem and aminoglycosides on methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa in vitro. Chemotherapy 2005;51:387-391.
22. Weiss K, Lapointe JR: Routine susceptibility testing of four antibiotic combinations for improvement of laboratory guide to therapy of cystic fibrosis infections caused by Pseudomonas aeruginosa. Antimicrob Agents Chemother 1995;39:2411-2114.
23. Bryan LE, Kwan S: Roles of ribosomal binding, membrane potential, and electron transport in bacterial uptake of streptomycin and gentamicin. Antimicrob Agents Chemother 1983;23:835-845.